KC-4630

SW780-ITGB6-KO(+/–) Cell Line

52748

Home » SW780-ITGB6-KO(+/--) Cell Line

Background of SW780-ITGB6-KO(+/--) Cell Line

Integrin beta-6 (ITGB6) is a subunit of the αvβ6 integrin heterodimer, which plays a crucial role in cell adhesion, migration, and signaling. ITGB6 is typically expressed at low levels in normal tissues but is significantly upregulated during tissue repair, inflammation, and in various cancers, including pancreatic, colorectal, and oral squamous cell carcinoma. Its overexpression is associated with tumor progression, metastasis, and poor prognosis, primarily through its interaction with extracellular matrix components like fibronectin and latent TGF-β, leading to TGF-β activation and subsequent promotion of epithelial-mesenchymal transition (EMT) and immune evasion. Due to its restricted expression in healthy tissues and strong association with aggressive cancer phenotypes, ITGB6 has emerged as a promising diagnostic biomarker and therapeutic target. Recent studies have explored the use of ITGB6-targeted antibodies, peptides, and imaging agents for cancer detection and treatment. However, further research is needed to fully elucidate its mechanistic roles and to develop safe and effective ITGB6-targeted therapies.

Specifications

Catalog Number	KC-4630
Cell Line Name	SW780-ITGB6-KO(+/–) Cell Line
Host Cell Line	SW780
Description	Stable SW780 clone with human ITGB6 gene knockout, No.2C1
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% L15+20% FBS+10% DMSO
Propagation Medium	L15+10% FBS
Selection Marker	N/A
Morphology	Epithelial
Subculture	Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 10⁵ cells/mL
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 30 hours
Mycoplasma Status	Negative

Cell Line Generation

SW780-ITGB6-KO(+/--) cell line was generated using the CRISPR method.

Characterization

Figure 1: Characterization of SW780-ITGB6-KO(+/--)-2C1 cell line stable clone using PCR sequencing.

Figure 2: Characterization of SW780-ITGB6-KO(+/--)-2C1 cell line stable clone using RT-PCR sequencing.

Figure 3: Characterization of SW780-ITGB6-KO(+/--)-2C1 cell line stable clone using FACS.

Cell Resuscitation

1. Prewarm culture medium (L15 + 10% FBS)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO₂ incubator.
8. Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 10⁵ cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% L15+ 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×10⁶ cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1. Ahmed, N., et al. (2002). Integrin αvβ6 expression in colon cancer. British Journal of Cancer, 86(8), 1276-1282.
2. Bandyopadhyay, A., & Raghavan, S. (2009). Defining the role of integrin αvβ6 in cancer. Current Cancer Drug Targets, 9(1), 72-81.
3. Marsh, D., et al. (2008). Integrin αvβ6 is a marker of poor prognosis in colorectal cancer. Clinical Cancer Research, 14(21), 7041-7048.